We describe a patient with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) that clinically resembled acute promyelocytic leukemia (APL). The karyotype of his leukemic cells was 46, XY, del (3) (q?) and did not include a chromosomal translocation involving the retinoic acid receptor-α gene. However, retinoic acid syndrome developed, and partial remission was achieved after treatment with all-trans retinoic acid (ATRA) followed by chemotherapy. Our case might provide new insights into the mechanism of the growth inhibitory effect of ATRA on APL-like cells.
Introduction
The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell diseases characterized by cytopenia, dysplasia in one or more of the major myeloid cell lines, and an increased risk of developing acute myeloid leukemia (AML) (1) . On the other hand, AML with myelodysplasia-related changes (AML-MRC), is classified into three categories: AML arising from previous MDS/ myeloproliferative neoplasm (MPN), AML with an MDSrelated cytogenetic abnormality, and AML with multilineage dysplasia (1) .
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) that accounts for approximately 10% of AML and displays unique characteristics, such as promyelocyte infiltration into the bone marrow, the presence of Auer rods and faggot cells, and the occurrence of disseminated intravascular coagulopathy (DIC) as a complication (2) . The characteristic chromosome and cytogenetic findings of APL are t(15;17) and the promyelocytic leukemia-retinoic acid receptor-α (PML-RARα) chimera gene (2) .
Here, we report a case of AML-MRC involving a deletion of the Q arm of chromosome 3, but not t(15;17), which displayed the morphological characteristics of APL and responded to ATRA, but did not possess the PML/RARα fusion transcript.
Case Report
We report the case of a 77-year-old man who complained of high fever and general malaise. He had been in good health, but then suddenly started to feel fatigued. Physical examinations at admission revealed systemic purpura and petechiae on his legs. No organomegaly was observed. His peripheral blood findings were as follows (Table 1) : white blood cell (WBC) count, 13,430/μL (neutrophils, 95%; lymphocytes, 3.9%; eosinophils, 0%; monocytes, 0.8%; basophils, 0.3%); hemoglobin, 4.4 g/dL; and platelet count, 1.2× 10 4 /μL. Coagulopathy was also detected: FDP, 63.6 μg/mL; D-dimer, 37.9 μg/mL; AT-III activity, 55.4%; TAT, 27.7 ng/ mL; and PIC, 13.3 ng/mL. These findings indicated the presence of disseminated intravascular coagulopathy (DIC) following the criteria of the Japanese Ministry of Health and Welfare (JMHW). Pretreatment DIC score was 4 (underlying disease: leukemia). Peripheral blood smears showed dysplastic neutrophils and a granular cytoplasm but no blastic cells or promyelocytes. Bone marrow (BM) aspiration revealed hyperplastic marrow cells, of which 3.8% were myeloblasts without granules (type I blasts) and 18.4% were abnormal type II blasts (Table 2) containing polymorphic nuclei, numerous azurophilic granules in their cytoplasm, and Auer rods (Fig. 1a ). These cells were remarkably similar to APL cells. Moreover, intense positivity for myeloperoxidase stain ( Fig. 1b) and negativity for α-naphthyl butyrate esterase and naphthol AS-D chloroacetate esterase were observed in all APL-like cells (data not shown). In addition, the neutrophils showed dysplastic morphological traits, such as giant metamyelocytes, multiple lobulated nuclei, and pseudo-Pelgerlike nuclei (Fig. 1c) . Signs of erythroid cell aplasia such as duplicated nuclei, megaloblastic changes (Fig. 1c) , and micro-megakaryocytes without platelets in their cytoplasm were also observed (Fig. 1d) , indicating multilineage dysplasia.
Immunophenotyping of the bone marrow blast cells produced the following results (Table 2) : CD13, 73.2%; CD33, 21.1%; CD34, 63.1%; and HLA-DR, 76.6%. These data are unusual for APL in that CD33 expression was weak, and the expression levels of CD34 and HLA-DR were strong (2) . A cytogenetic assessment of the BM cells was performed according to standard methods using the Giemsa-banding technique. Although, no abnormalities were detected in chromosomes 15 or 17, including t(15;17), in any sample, del of the chromosome and cytogenetic analyses. The continuous infusion of low-molecular weight heparin was also started as a therapy for DIC. On day 2 of the ATRA treatment, the patent's WBC count rose rapidly to exceed 20,000/μL, chest X-ray showed an enlarged cardiac shadow, and the patient developed respiratory failure (Fig. 2) . As we considered that the patient had developed retinoic acid syndrome, we added steroid treatment and diuretic and cytotoxic chemotherapy with idarubicin and cytarabine. Two days later, the patient recovered from his respiratory failure.
Although these therapies also improved his coagulopathy and WBC count, the data obtained on admission showed no evidence of PML/RARα rearrangement, and the reverse transcriptase-polymerase chain reaction (RT-PCR) did not detect the PML/RARα fusion transcript in his bone marrow sample. Moreover, fluorescence in situ hybridization (FISH) performed on interphase nuclei using a PML/RARα dual color dual fusion translocation probe showed separate PML and RARα signals in all nuclei (data not shown). This indicated that no PML/RARα fusion signal was present and that no translocation of the RARα gene to other genes had occurred. However, we continued administration of oral ATRA at a dose of 45 mg/m 2 /day because a good response was seen. Forty days after the start of the therapy, the patient 
Discussion
Although we could not find any data indicating that the patient had a history of MDS, the peripheral blood and BM smear findings observed in this case were indicative of multilineage dysplasia. Interestingly, the immature cells did not show the usual blastic morphology, and the majority of these cells contained many granules in their cytoplasm and a blastic nucleus with nucleoli, which are suggestive of promyelocytes.
The chromosome aberration observed in the present case involved the deletion of the Q arm of chromosome 3, which is not considered to be an MDS-related cytogenetic abnormalitiy (1). Grigg et al reported that 3q abnormalities are seen in about 2% of patients presenting with AML or MDS and that these patients should be considered to have a poor prognosis. However, in their analysis, there were no APL cases or cases in which MDS was transformed to APL involving a 3q abnormality (3) . Moreover, APL is not generally associated with multilineage dysplasia.
Until the laboratory findings of the chromosome and cytogenetic analyses were obtained we thought that the present case was APL, and treatment with ATRA was initiated. Among the previous cases of APL that were treated with ATRA, approximately 25 percent of patients developed "retinoic acid syndrome", which was characterized by fever, respiratory failure, pulmonary infiltration, pleural effusion, and weight gain. This syndrome can occur as early as the second day of treatment and as late as the third week (2), but its cause is unclear. In the present case, pulmonary infiltration and respiratory failure occurred on the second day of treatment. These complications and the patient's response to ATRA did not conflict with our early diagnosis of APL. However, the cytogenetic results, which were reported later, were not typical of APL.
A diagnosis of APL can be established based on not only morphological analysis but also cytogenetic and molecular studies. The WHO classification has incorporated recently acquired genetic information into an updated classification scheme for AML (1) . APL is categorized into two groups: the t(15;17) (q22;q12) positive group and the PML-RARα chimera gene positive patients without t(15;17) (q22;q 12) (1). Recently, some cases with morphological features resembling APL and variant translocations involving the RARα gene have been reported (4) (5) (6) (7) . However, the WHO classification mentions that these cases should be diagnosed as AML with a variant RARα translocation since the morphological features and clinical courses of these cases are not typical of APL (1). Yamamoto et al identified BCL-6 interacting corepressor (BCOR) as the newest fusion partner of RARα in a t(X;17) (p11;q12) variant translocation. The leukemia cells in their patient also showed a unique morphology with round inclusions and rectangular cytoplasmic bodies (8) .
In the present case, the reverse transcriptase-polymerase chain reaction (RT-PCR) did not detect the PML/RARα fusion transcript, and FISH analysis indicated that the PML/ RARα fusion signal was not present and that no variant translocation of the RARα gene to other genes had occurred.
We finally decided that this case was AML with MRC, and not APL, because the patient's multilineage dysplasia, CD34 + and HLA-DR + immunophenotype, and karyotype abnormality [del(3)(q?)] and the absence of a RARα gene translocation did not agree with a diagnosis of APL. Previously, Najfeld et al reported 2 cases of MDS that were transformed to "APL-like leukemia" with chromosome 11 trisomy. The immunophenotype of their leukemia cells was CD34 + (both patients) and HLA-DR + (data only available for one patient), and they possessed wild type RARα genes without the PML-RARα chimera gene (both patients). Moreover, both patients failed to respond to ATRA treatment (9) . On the other hand, Wolach et al reported a case of therapy-related APL developing through a phase of therapyrelated MDS, which responded to ATRA treatment. However, in their case, both RT-PCR for the PML-RARα and FISH result were positive (10) .
To our surprise, the present case responded to ATRA, and partial remission was achieved in the absence of the PML-RARα chimera gene. Retinoids are signaling molecules that play important roles in cell growth, differentiation, and death. They act through two types of intracellular receptor, retinoic acid receptors (RAR) and retinoid X receptors (RXR). ATRA binds to and activates not only RARα but also other RAR subtypes, while bexarotene activates RXR (11) . Retinoids have been successfully used in the treatment of APL. Pharmacologic doses of ATRA were found to counteract the inhibitory effect of the PML-RARα fusion protein and permit transcriptional activation leading to leukemic cell differentiation (11) . Moreover, it has recently been demonstrated that retinoids suppress carcinogenesis in several tissue types (11) . For example, Seewaldt et al demonstrated ATRA-induced cell cycle arrest and apoptosis in RARα-transduced human breast cancer cell lines (12) . Moreover, adding ATRA to chemotherapy increases the response rate and progression-free survival in patients with advanced non-small-cell lung cancer (13) . Hence, one possible antitumoral mechanism for the effects of ATRA seen in the present case is the induction and/or activation of different RAR subtypes followed by apoptosis.
Conclusion
Here, we describe a case of AML-MRC that clinically resembled APL. Although the patient did not possess the typical chromosomal and cytogenetic abnormalities of APL or the PML/RARα fusion transcript, he responded to ATRA, and his coagulopathy was improved. More studies are needed to clarify the relationship between APL-like cells and myelodysplasia-related changes and the utility of ATRA for treating leukemia, especially in RARα fusion gene negative cases.
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